Human CD269/TNFRSF17/BCMA Antibody (BCMB69) is a research-grade biosimilar monoclonal antibody targeting CD269. It is a human IgG4 antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Tumor necrosis factor receptor superfamily member 17 (CD269/BCMA) is a ~20 kDa protein. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. CD269 is the therapeutic target of teclistamab (Tecvayli).